<h4>Background</h4>Glucagon-like peptide-1 receptor (GLP1R) agonists reduce cardiovascular events in patients with obesity and diabetes, and recent trials demonstrate symptomatic and functional benefits in heart failure with preserved ejection fraction (HFpEF). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.